responding to the opioid problem: new directions in research by jack b. stein, msw, phd
TRANSCRIPT
![Page 1: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/1.jpg)
Jack B. Stein, MSW, PhDNational Institute on Drug Abuse
Opioid Overdose SummitAnn Arbor, MI
December 1, 2015
Responding to the Opioid Problem:
New Directions in Research
1
![Page 2: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/2.jpg)
Nora D. Volkow, MDDirector
2
![Page 3: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/3.jpg)
Addressing the Opioid Crisis:NIDA Research Priorities
• Alternative approaches to treating pain• Preventing opioid (and other drug) use
disorders• Preventing overdose deaths• Treating opioid use disorders• Implementing evidence-based findings
3
![Page 4: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/4.jpg)
Pain: Treatment Alternatives
• Biomarkers to detect pain• Abuse deterrent formulations• Alternatives to medications:– Transcranial Magnetic Stimulation– Transcranial Direct Current
Stimulation– High-Definition Transcranial Direct
Current Stimulation– Deep Brain Stimulation
4
![Page 5: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/5.jpg)
** **
PREVENTION: Universal Interventions
R. Spoth et al. American Journal of Public Health 2013
** p<.01
Age 25 General Age 25 Opioids0%
4%
8%
12%
16% 15.5%
13.5%
5.4%4.7%
ControlFamily Program
5
(narcotics, depressants, stimulants)
Brief universal interventions in early adolescence can reduce prescription drug misuse into young adulthood.
![Page 6: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/6.jpg)
OVERDOSE: User-Friendly Naloxone
• April 3, 2014: FDA approval of naloxone auto-injector (“Evzio”)
• November 18, 2015: FDA approval of naloxone nasal spray (“Narcan Nasal Spray”)
6
![Page 7: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/7.jpg)
TREATMENT: Anti-Addiction Medications
• Lower dose; slower release•Mixture formulations (e.g., naloxone and
buprenorphine) • “Prodrug” formulations (only activated
via digestion)• Long-acting (e.g., subdermal buprenorphine
implants)• Vaccines• Alternatives to medication (e.g., TMS)
7
![Page 8: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/8.jpg)
Implementation: MAT Utilization
Medication % programs using MAT
(N=345)
% of eligible patients
receiving MAT (w/in adopting
programs)
Methadone 7.8 41.3Buprenorphine
20.9 37.3Tablet naltrexone
22.0 10.9
Knudsen et al, 2011, J Addict Med; 5:21-27.
8
![Page 9: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/9.jpg)
Implementation: Addiction Medications as Prevention
-10,000
-8,000
-6,000
-4,000
-2,000
-0 Pati
ents
Tre
ated
Heroin OD Buprenorphine Treatment Methadone Treatment
300-
200-
100-
0-Ove
rdos
e D
eath
s
R Schwartz et al. American Journal of Public Health 20139
![Page 10: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/10.jpg)
Buprenorphine Referral Brief Intervention0
10
20
30
40
50
60
70
80
90
78%
37%45%
% e
ngag
ed in
tre
atm
ent
on t
he 3
0th da
y af
ter
rand
omiz
atio
n
5.4
2.3
Number of days of illicit opiate use per week
5.4
0.9
5.6
2.4
D’Onofrio, et al. JAMA. 2015.
Implementation: MAT in EDs and Treatment
Retention
10
![Page 11: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/11.jpg)
Federal Resources
11
hhs.gov/opioids/
![Page 12: Responding to the Opioid Problem: New Directions in Research by Jack B. Stein, MSW, PhD](https://reader035.vdocuments.us/reader035/viewer/2022070602/587ae1ca1a28ab542b8b679b/html5/thumbnails/12.jpg)
drugabuse.gov
NIDA Resources
12